

# Commercial PA Criteria Effective: February 20, 2020

Prior Authorization: Valtoco - Libervant

Products Affected: Valtoco (diazepam) nasal spray, Libervant (diazepam) buccal film

<u>Medication Description</u>: The exact mechanism of action for diazepam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAa receptor.

**Covered Uses:** Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy.

#### **Exclusion Criteria:**

1. Known hypersensitivity to diazepam

#### **Required Medical Information:**

- 1. Diagnosis
- 2. Current therapy regimen

#### Age Restrictions:

- 1. Valtoco 6 years of age and older
- 2. Libervant 2-5 years of age

**Prescriber Restrictions:** The medication is prescribed by or in consultation with a neurologist.

### Coverage Duration: 12 months

#### **Other Criteria:**

- 1. Intermittent, stereotypic episodes of frequent seizure activity Approve if the patient meets the following
  - A. Patient has a diagnosis of intermittent episodes of frequent Seizure activity (i.e., seizure clusters, acute repetitive seizures); **AND**
  - B. Patient is currently receiving treatment with maintenance antiseizure medication(s).

#### References:

- 1. Valtoco<sup>®</sup> nasal spray [prescribing information]. San Diego, CA: Neurelis, Inc.; January 2020.
- 2. Libervant (diazepam) [prescribing information]. Warren, NJ: Aquestive Therapeutics; April 2024.

May 2024

# ConnectiCare.

## Policy Revision history

| Rev # | Type of Change | Summary of Change   | Sections Affected  | Date      |
|-------|----------------|---|--|-----------|
| 1     | New Policy     | New Policy  | All  | 4/7/2020  |
| 2     | Policy Update  | Addition of Libervant diazepam) buccal<br>film to the policy<br>Addition of prescriber restrictions "The<br>medication is prescribed by or in<br>consultation with a neurologist."<br>Addition of age 2-5 years old for Libervant | Prior Authorization<br>Products Affected<br>Prescriber Restrictions<br>Age restriction | 5/23/2024 |



May 2024